Immutep Limited (PRRUF)
OTCMKTS · Delayed Price · Currency is USD
0.2535
-0.0675 (-21.03%)
At close: Jan 6, 2026
Immutep Revenue
In the fiscal year ending June 30, 2025, Immutep had annual revenue of 5.04M AUD with 31.28% growth. Immutep had revenue of 1.90M in the half year ending June 30, 2025, with 4.17% growth.
Revenue
5.04M AUD
Revenue Growth
+31.28%
P/S Ratio
118.96
Revenue / Employee
162.70K AUD
Employees
31
Market Cap
393.37M USD
Revenue Chart
* This company reports financials in AUD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 5.04M | 1.20M | 31.28% |
| Jun 30, 2024 | 3.84M | 336.16K | 9.59% |
| Jun 30, 2023 | 3.51M | -1.21M | -25.64% |
| Jun 30, 2022 | 4.71M | 851.56K | 22.04% |
| Jun 30, 2021 | 3.86M | -9.88M | -71.88% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioStem Technologies | 292.21M |
| Vaxart | 148.20M |
| Silence Therapeutics | 25.83M |
| Nuo Therapeutics | 2.61M |
| Northwest Biotherapeutics | 937.00K |
| ZIVO Bioscience | 209.03K |
| Arch Biopartners | 198.11K |
Immutep News
- 7 weeks ago - Immutep Announces Positive Update on IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases, from Phase I Study - GlobeNewsWire
- 2 months ago - India's Dr Reddy's signs licensing pact to sell Immutep's cancer drug - Reuters
- 2 months ago - Dr. Reddy’s Laboratories enters strategic collaboration with Immutep SAS for exclusive licensing of eftilagimod alfa - Business Upturn
- 4 months ago - Immutep Limited (IMMP) Presents at ESMO Congress 2025 - Slideshow - Seeking Alpha
- 4 months ago - Primary Endpoint Met in EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma and Data Presented at ESMO Congress 2025 - GlobeNewsWire
- 5 months ago - Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025 - GlobeNewsWire
- 7 months ago - Immutep Quarterly Activities Report Q4 FY25 - GlobeNewsWire
- 7 months ago - Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer - GlobeNewsWire